BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, Yellin O, Nichols CM, Dreyer MP, Ahles CP, Robinson A, Madden E, Waterman GN, Swift RA, Bonavida B, Boccia R, Vescio RA, Crowley J, Chen H, Berenson JR. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol 2012;158:727-38. [PMID: 22804669 DOI: 10.1111/j.1365-2141.2012.09241.x] [Cited by in Crossref: 120] [Cited by in F6Publishing: 117] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Hoi AY, Harris J, Mackay F, Morand EF. Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus. Clin Transl Immunology 2019;8:e01047. [PMID: 31024730 DOI: 10.1002/cti2.1047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
2 Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, Fellowes VS, Hakim FT, Gress RE, Kochenderfer JN. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 2016;128:1688-700. [PMID: 27412889 DOI: 10.1182/blood-2016-04-711903] [Cited by in Crossref: 396] [Cited by in F6Publishing: 388] [Article Influence: 79.2] [Reference Citation Analysis]
3 Tian Z, Liu M, Zhang Y, Wang X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol 2021;14:75. [PMID: 33941237 DOI: 10.1186/s13045-021-01084-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Atrash S, Moyo TK. A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma. Onco Targets Ther 2021;14:2185-201. [PMID: 33814917 DOI: 10.2147/OTT.S242018] [Reference Citation Analysis]
5 Offidani M, Corvatta L, Morè S, Olivieri A. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety. Drug Des Devel Ther 2021;15:2401-15. [PMID: 34103900 DOI: 10.2147/DDDT.S267404] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Wang JZ, Zhang YH, Guo XH, Zhang HY, Zhang Y. The double-edge role of B cells in mediating antitumor T-cell immunity: Pharmacological strategies for cancer immunotherapy. Int Immunopharmacol 2016;36:73-85. [PMID: 27111515 DOI: 10.1016/j.intimp.2016.04.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
7 Oriol A, Abril L, Torrent A, Ibarra G, Ribera JM. The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma. Ther Adv Hematol 2021;12:20406207211019622. [PMID: 34104374 DOI: 10.1177/20406207211019622] [Reference Citation Analysis]
8 Li DH, Yang Q, Zhou JS, Zhang ZW, Miao MY, Yang SS, Xu WD. Regulatory role of B-cell maturation antigen on the toxic effect of chromium ions on human SaOS-2 osteoblasts. Biotechnol Appl Biochem 2017;64:638-46. [PMID: 26011700 DOI: 10.1002/bab.1401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Jew S, Chang T, Bujarski S, Soof C, Chen H, Safaie T, Li M, Sanchez E, Wang C, Spektor TM, Emamy-Sadr M, Swift R, Rahbari A, Patil S, Souther E, Berenson JR. Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment. Br J Haematol 2021;192:272-80. [PMID: 32441777 DOI: 10.1111/bjh.16752] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
10 Chen H, Li M, Xu N, Ng N, Sanchez E, Soof CM, Patil S, Udd K, Bujarski S, Cao J, Hekmati T, Ghermezi M, Zhou M, Wang EY, Tanenbaum EJ, Zahab B, Schlossberg R, Yashar MA, Wang CS, Tang GY, Spektor TM, Berenson JR. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells. Leukemia Research 2019;81:62-6. [DOI: 10.1016/j.leukres.2019.04.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
11 Ghermezi M, Li M, Vardanyan S, Harutyunyan NM, Gottlieb J, Berenson A, Spektor TM, Andreu-Vieyra C, Petraki S, Sanchez E, Udd K, Wang CS, Swift RA, Chen H, Berenson JR. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica 2017;102:785-95. [PMID: 28034989 DOI: 10.3324/haematol.2016.150896] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 11.2] [Reference Citation Analysis]
12 Kocoglu MH, Badros AZ. Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond. Expert Rev Hematol 2020;13:669-86. [PMID: 32290719 DOI: 10.1080/17474086.2020.1756258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wang Y, Li H, Xu W, Pan M, Qiao C, Cai J, Xu J, Wang M, Zhang J. BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma. Journal of Immunotherapy 2020;43:175-88. [DOI: 10.1097/cji.0000000000000320] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
14 Jackson DA, Elsawa SF. Factors regulating immunoglobulin production by normal and disease-associated plasma cells. Biomolecules 2015;5:20-40. [PMID: 25615546 DOI: 10.3390/biom5010020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
15 Foster LH, Lum LG. Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs. Expert Opin Biol Ther 2019;19:707-20. [PMID: 31081696 DOI: 10.1080/14712598.2019.1604672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 Harutyunyan NM, Vardanyan S, Ghermezi M, Gottlieb J, Berenson A, Andreu-vieyra C, Berenson JR. Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients. Br J Haematol 2016;174:81-7. [DOI: 10.1111/bjh.14026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
17 Abramson HN. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. Int J Mol Sci 2020;21:E5192. [PMID: 32707894 DOI: 10.3390/ijms21155192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
18 Ishibashi M, Soeda S, Sasaki M, Handa H, Imai Y, Tanaka N, Tanosaki S, Ito S, Odajima T, Sugimori H, Asayama T, Sunakawa M, Kaito Y, Kinoshita R, Kuribayashi Y, Onodera A, Moriya K, Tanaka J, Tsukune Y, Komatsu N, Inokuchi K, Tamura H. Clinical impact of serum soluble SLAMF7 in multiple myeloma. Oncotarget 2018;9:34784-93. [PMID: 30410677 DOI: 10.18632/oncotarget.26196] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
19 Xia J, Xu H, Zhang X, Allamargot C, Coleman KL, Nessler R, Frech I, Tricot G, Zhan F. Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid. EBioMedicine 2017;18:41-9. [PMID: 28229908 DOI: 10.1016/j.ebiom.2017.02.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
20 Demel I, Bago JR, Hajek R, Jelinek T. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021. Br J Haematol 2021;193:705-22. [PMID: 33216972 DOI: 10.1111/bjh.17235] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
21 Abramson HN. Immunotherapy of Multiple Myeloma: Promise and Challenges. Immunotargets Ther 2021;10:343-71. [PMID: 34527606 DOI: 10.2147/ITT.S306103] [Reference Citation Analysis]
22 Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Hoos A, Gupta I, Bragulat V, He Z, Opalinska JB, Cohen AD. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J 2019;9:37. [PMID: 30894515 DOI: 10.1038/s41408-019-0196-6] [Cited by in Crossref: 102] [Cited by in F6Publishing: 99] [Article Influence: 51.0] [Reference Citation Analysis]
23 Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson LD Jr, Sutherland HJ, Yong K, Hoos A, Gorczyca MM, Lahiri S, He Z, Austin DJ, Opalinska JB, Cohen AD. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol 2018;19:1641-53. [PMID: 30442502 DOI: 10.1016/S1470-2045(18)30576-X] [Cited by in Crossref: 113] [Cited by in F6Publishing: 75] [Article Influence: 37.7] [Reference Citation Analysis]
24 Huang H, Wu HW, Hu YX. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma. J Zhejiang Univ Sci B 2020;21:29-41. [PMID: 31898440 DOI: 10.1631/jzus.B1900351] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
25 Nadeem O, Tai YT, Anderson KC. Immunotherapeutic and Targeted Approaches in Multiple Myeloma. Immunotargets Ther 2020;9:201-15. [PMID: 33117743 DOI: 10.2147/ITT.S240886] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
26 Rodríguez-Lobato LG, Ganzetti M, Fernández de Larrea C, Hudecek M, Einsele H, Danhof S. CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions. Front Oncol 2020;10:1243. [PMID: 32850376 DOI: 10.3389/fonc.2020.01243] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 24.0] [Reference Citation Analysis]
27 Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Y, Eades B, Swift R, Berenson JR. Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic. Ann Hematol 2017;96:441-8. [PMID: 27913860 DOI: 10.1007/s00277-016-2888-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
28 Teoh PJ, Chng WJ. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J 2021;11:84. [PMID: 33927192 DOI: 10.1038/s41408-021-00469-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
29 Sanchez E, Li M, Patil S, Soof CM, Nosrati JD, Schlossberg RE, Vidisheva A, Tanenbaum EJ, Hekmati T, Zahab B, Wang C, Tang G, Chen H, Berenson JR. The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo. Ann Hematol 2019;98:691-703. [DOI: 10.1007/s00277-019-03595-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
30 Jew S, Bujarski S, Soof C, Chen H, Safaie T, Li M, Sanchez E, Wang C, Emamy-Sadr M, Swift R, Rahbari A, Patil S, Souther E, Spektor TM, Berenson JR. Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patients. Br J Haematol 2021;192:1064-7. [PMID: 32321191 DOI: 10.1111/bjh.16673] [Reference Citation Analysis]
31 Romano A, Storti P, Marchica V, Scandura G, Notarfranchi L, Craviotto L, Di Raimondo F, Giuliani N. Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma. Front Oncol 2021;11:684561. [PMID: 34307150 DOI: 10.3389/fonc.2021.684561] [Reference Citation Analysis]
32 Cohen AD. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update. American Society of Clinical Oncology Educational Book 2018. [DOI: 10.1200/edbk_200889] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
33 Tamura H, Ishibashi M, Sunakawa M, Inokuchi K. Immunotherapy for Multiple Myeloma. Cancers (Basel). 2019;11:2009. [PMID: 31842518 DOI: 10.3390/cancers11122009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
34 Sheikh S, Lebel E, Trudel S. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma. Future Oncol 2020;16:2783-98. [PMID: 32875817 DOI: 10.2217/fon-2020-0521] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
35 Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens T. Chimeric Antigen Receptor (CAR) therapy for multiple myeloma. Br J Haematol 2016;172:685-98. [DOI: 10.1111/bjh.13889] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
36 Betts A, van der Graaf PH. Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology. Clin Pharmacol Ther 2020;108:528-41. [PMID: 32579234 DOI: 10.1002/cpt.1961] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
37 Hammood M, Craig AW, Leyton JV. Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development. Pharmaceuticals (Basel) 2021;14:674. [PMID: 34358100 DOI: 10.3390/ph14070674] [Reference Citation Analysis]
38 Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol 2020;13:125. [PMID: 32943087 DOI: 10.1186/s13045-020-00962-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 19.0] [Reference Citation Analysis]
39 Caraccio C, Krishna S, Phillips DJ, Schürch CM. Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions. Front Immunol 2020;11:501. [PMID: 32391000 DOI: 10.3389/fimmu.2020.00501] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 30.0] [Reference Citation Analysis]
40 Udd KA, Bujarski S, Wirtschafter E, Spektor TM, Ghermezi M, Rassenti LZ, David ME, Nosrati JD, Rahbari AA, Wang J, Vardanyan S, Harutyunyan NM, Linesch J, Li M, Sanchez E, Chen H, Kipps TJ, Berenson JR. Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia. Targ Oncol 2019;14:551-61. [DOI: 10.1007/s11523-019-00666-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
41 Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-Drug Conjugates for Cancer Therapy. Molecules 2020;25:E4764. [PMID: 33081383 DOI: 10.3390/molecules25204764] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
42 Visram A, Soof C, Rajkumar SV, Kumar SK, Bujarski S, Spektor TM, Kyle RA, Berenson JR, Dispenzieri A. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer J 2021;11:120. [PMID: 34168119 DOI: 10.1038/s41408-021-00505-4] [Reference Citation Analysis]
43 Atrash S, Bano K, Harrison B, Abdallah AO. CAR-T treatment for hematological malignancies. J Investig Med 2020;68:956-64. [PMID: 32200355 DOI: 10.1136/jim-2020-001290] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
44 Dogan A, Siegel D, Tran N, Fu A, Fowler J, Belani R, Landgren O. B-cell maturation antigen expression across hematologic cancers: a systematic literature review. Blood Cancer J 2020;10:73. [PMID: 32606424 DOI: 10.1038/s41408-020-0337-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
45 van Rhee F. Engineering more efficacious antibody therapy for myeloma. Blood 2014;123:3062-3. [PMID: 24832938 DOI: 10.1182/blood-2014-04-560342] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
46 Eckhert E, Hewitt R, Liedtke M. B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma. Immunotherapy 2019;11:801-11. [PMID: 31094254 DOI: 10.2217/imt-2018-0199] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
47 Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, Zhang YL, Wang FX, Zhang PY, Lei B, Gu LF, Wang JL, Yang N, Zhang R, Zhang H, Shen Y, Bai J, Xu Y, Wang XG, Zhang RL, Wei LL, Li ZF, Li ZZ, Geng Y, He Q, Zhuang QC, Fan XH, He AL, Zhang WG. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol 2018;11:141. [PMID: 30572922 DOI: 10.1186/s13045-018-0681-6] [Cited by in Crossref: 183] [Cited by in F6Publishing: 181] [Article Influence: 61.0] [Reference Citation Analysis]
48 Fontana F, Ge X, Su X, Hathi D, Xiang J, Cenci S, Civitelli R, Shoghi KI, Akers WJ, D'avignon A, Weilbaecher KN, Shokeen M. Evaluating Acetate Metabolism for Imaging and Targeting in Multiple Myeloma. Clin Cancer Res 2017;23:416-29. [PMID: 27486177 DOI: 10.1158/1078-0432.CCR-15-2134] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
49 Dalla Palma B, Marchica V, Catarozzo MT, Giuliani N, Accardi F. Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma. J Clin Med 2020;9:E3022. [PMID: 32961764 DOI: 10.3390/jcm9093022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
50 Yu B, Liu D. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J Hematol Oncol 2019;12:94. [PMID: 31500657 DOI: 10.1186/s13045-019-0786-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 21.0] [Reference Citation Analysis]
51 Meinl E, Krumbholz M. Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma. Curr Opin Immunol 2021;71:117-23. [PMID: 34330018 DOI: 10.1016/j.coi.2021.06.015] [Reference Citation Analysis]
52 Godara A, Zhou P, Kugelmass A, Ma X, Rosenthal B, Toskic D, Fogaren T, Varga C, Comenzo RL. Presence of soluble and cell‐surface B‐cell maturation antigen in systemic light‐chain amyloidosis and its modulation by gamma‐secretase inhibition. Am J Hematol 2020;95. [DOI: 10.1002/ajh.25734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
53 Robinson AA, Wang J, Vardanyan S, Madden EK, Hebroni F, Udd KA, Spektor TM, Nosrati JD, Kitto AZ, Zahab M, Cheema S, Fors DH, Norberg A, Diehl J, Waterman GN, Swift RA, Crowley J, Berenson JR. Risk of skin cancer in multiple myeloma patients: a retrospective cohort study. Eur J Haematol 2016;97:439-44. [DOI: 10.1111/ejh.12748] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
54 Cho SF, Anderson KC, Tai YT. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Front Immunol 2018;9:1821. [PMID: 30147690 DOI: 10.3389/fimmu.2018.01821] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 36.0] [Reference Citation Analysis]
55 Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W, Hoang B, Tunstead J, Christie AL, Kung AL, Richardson P, Munshi NC, Anderson KC. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 2014;123:3128-38. [PMID: 24569262 DOI: 10.1182/blood-2013-10-535088] [Cited by in Crossref: 227] [Cited by in F6Publishing: 215] [Article Influence: 32.4] [Reference Citation Analysis]
56 Sanchez E, Tanenbaum EJ, Patil S, Li M, Soof CM, Vidisheva A, Waterman GN, Hekmati T, Tang G, Wang CS, Chen H, Berenson J. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. Expert Review of Molecular Diagnostics 2018;18:319-29. [DOI: 10.1080/14737159.2018.1448269] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
57 Xu J, Wang Q, Xu H, Gu C, Jiang L, Wang J, Wang D, Xu B, Mao X, Wang J, Wang Z, Xiao Y, Zhang Y, Li C, Zhou J. Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma. J Hematol Oncol 2018;11:128. [PMID: 30348186 DOI: 10.1186/s13045-018-0672-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
58 Sanchez L, Dardac A, Madduri D, Richard S, Richter J. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies. Ther Adv Hematol 2021;12:2040620721989585. [PMID: 33796236 DOI: 10.1177/2040620721989585] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
59 Swan D, Routledge D, Harrison S. The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies. Br J Haematol 2021. [PMID: 34472091 DOI: 10.1111/bjh.17805] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Stauffer A, Ray C, Hall M. A Flexible Multiplatform Bioanalytical Strategy for Measurement of Total Circulating Shed Target Receptors: Application to Soluble B Cell Maturation Antigen Levels in the Presence of a Bispecific Antibody Drug. Assay Drug Dev Technol 2021;19:17-26. [PMID: 33232610 DOI: 10.1089/adt.2020.1024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Ntanasis-Stathopoulos I, Gavriatopoulou M, Terpos E. Antibody therapies for multiple myeloma. Expert Opin Biol Ther 2020;20:295-303. [PMID: 31944131 DOI: 10.1080/14712598.2020.1717464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
62 Cohen AD. Myeloma: next generation immunotherapy. Hematology Am Soc Hematol Educ Program 2019;2019:266-72. [PMID: 31808859 DOI: 10.1182/hematology.2019000068] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
63 Fonseca R, Gonzalez-Velez M. Treatment of Smoldering Multiple Myeloma: Expectant Observation Should Still Be the Standard. Am Soc Clin Oncol Educ Book 2020;40:1-7. [PMID: 32207672 DOI: 10.1200/EDBK_280179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
64 Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y, Zhang X, Mendonça M, Majewski N, Nanjunda R, Chin D, Packman K, Elsayed Y, Attar R, Gaudet F. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv 2020;4:4538-49. [PMID: 32956453 DOI: 10.1182/bloodadvances.2020002393] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
65 Podar K, Pecherstorfer M. Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma. Expert Opin Pharmacother 2017;18:1061-79. [PMID: 28604120 DOI: 10.1080/14656566.2017.1340942] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
66 Maples KT, Joseph NS, Harvey RD. Current developments in the combination therapy of relapsed/refractory multiple myeloma. Expert Rev Anticancer Ther 2020;20:1021-35. [PMID: 32969752 DOI: 10.1080/14737140.2020.1828071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
67 Braunstein M, Weltz J, Davies F. A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma. Expert Rev Hematol 2021;14:377-89. [PMID: 33769179 DOI: 10.1080/17474086.2021.1909469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
68 Ferron-Brady G, Rathi C, Collins J, Struemper H, Opalinska J, Visser S, Jewell RC. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma. Clin Pharmacol Ther 2021;110:1282-92. [PMID: 34468979 DOI: 10.1002/cpt.2409] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res 2013;19:2048-60. [PMID: 23344265 DOI: 10.1158/1078-0432.CCR-12-2422] [Cited by in Crossref: 308] [Cited by in F6Publishing: 218] [Article Influence: 38.5] [Reference Citation Analysis]
70 Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, Rattel B, Adam PJ, Anderson KC, Friedrich M. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia 2017;31:1743-51. [PMID: 28025583 DOI: 10.1038/leu.2016.388] [Cited by in Crossref: 107] [Cited by in F6Publishing: 103] [Article Influence: 21.4] [Reference Citation Analysis]
71 Chen Y, Nagarajan C, Tan MS, Martinelli G, Cerchione C. BCMA-targeting approaches for treatment of multiple myeloma. Panminerva Med 2021;63:28-36. [PMID: 32955181 DOI: 10.23736/S0031-0808.20.04121-X] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Nooka AK, Weisel K, van de Donk NW, Routledge D, Otero PR, Song K, Quach H, Callander N, Minnema MC, Trudel S, Jackson NA, Ahlers CM, Im E, Cheng S, Smith L, Hareth N, Ferron-Brady G, Brouch M, Montes de Oca R, Paul S, Holkova B, Gupta I, Kremer BE, Richardson P. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. Future Oncol 2021;17:1987-2003. [PMID: 33682447 DOI: 10.2217/fon-2020-1269] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
73 Sanchez E, Smith EJ, Yashar MA, Patil S, Li M, Porter AL, Tanenbaum EJ, Schlossberg RE, Soof CM, Hekmati T, Tang G, Wang CS, Chen H, Berenson JR. The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma. Target Oncol 2018;13:39-47. [PMID: 29230672 DOI: 10.1007/s11523-017-0538-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
74 Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, Milone MC. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest 2019;129:2210-21. [PMID: 30896447 DOI: 10.1172/JCI126397] [Cited by in Crossref: 223] [Cited by in F6Publishing: 137] [Article Influence: 111.5] [Reference Citation Analysis]
75 Bujarski S, Udd K, Soof C, Chen H, Spektor TM, Safaie T, Li M, Stern J, Wang C, Xu N, Emamy-Sadr M, Swift R, Rahbari A, Patil S, Souther E, Regidor B, Sutanto C, Berenson JR. Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy. Target Oncol 2021;16:503-15. [PMID: 34097243 DOI: 10.1007/s11523-021-00821-6] [Reference Citation Analysis]
76 Jasiński M, Basak GW, Jedrzejczak WW. Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma. Front Immunol 2021;12:632937. [PMID: 33717171 DOI: 10.3389/fimmu.2021.632937] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Bunse M, Pfeilschifter J, Bluhm J, Zschummel M, Joedicke JJ, Wirges A, Stark H, Kretschmer V, Chmielewski M, Uckert W, Abken H, Westermann J, Rehm A, Höpken UE. CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin's lymphoma and tumor-supportive follicular T helper cells. Nat Commun 2021;12:240. [PMID: 33431832 DOI: 10.1038/s41467-020-20488-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
78 Schuh E, Musumeci A, Thaler FS, Laurent S, Ellwart JW, Hohlfeld R, Krug A, Meinl E. Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement. J I 2017;198:3081-8. [DOI: 10.4049/jimmunol.1601746] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
79 Lam N, Trinklein ND, Buelow B, Patterson GH, Ojha N, Kochenderfer JN. Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. Nat Commun 2020;11:283. [PMID: 31941907 DOI: 10.1038/s41467-019-14119-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 27.0] [Reference Citation Analysis]
80 Rotolo A, Caputo V, Karadimitris A. The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma. Br J Haematol 2016;173:350-64. [DOI: 10.1111/bjh.13976] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
81 Egan P, Drain S, Conway C, Bjourson AJ, Alexander HD. Towards Stratified Medicine in Plasma Cell Myeloma. Int J Mol Sci 2016;17:E1760. [PMID: 27775669 DOI: 10.3390/ijms17101760] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Ravi P, Kumar S, Gonsalves W, Buadi F, Lacy MQ, Go RS, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. Blood Cancer J 2017;7:e569. [PMID: 28622306 DOI: 10.1038/bcj.2017.46] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
83 Hengeveld PJ, Kersten MJ. B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? Blood Cancer J 2015;5:e282. [PMID: 25723853 DOI: 10.1038/bcj.2015.3] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 8.8] [Reference Citation Analysis]
84 Gavriatopoulou M, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E. Anti-BCMA antibodies in the future management of multiple myeloma. Expert Rev Anticancer Ther 2019;19:319-26. [PMID: 30810049 DOI: 10.1080/14737140.2019.1586539] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
85 McMillan A, Warcel D, Popat R. Antibody-drug conjugates for multiple myeloma. Expert Opin Biol Ther 2021;21:889-901. [PMID: 32729730 DOI: 10.1080/14712598.2020.1802422] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
86 Laurent SA, Hoffmann FS, Kuhn PH, Cheng Q, Chu Y, Schmidt-Supprian M, Hauck SM, Schuh E, Krumbholz M, Rübsamen H, Wanngren J, Khademi M, Olsson T, Alexander T, Hiepe F, Pfister HW, Weber F, Jenne D, Wekerle H, Hohlfeld R, Lichtenthaler SF, Meinl E. γ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun 2015;6:7333. [PMID: 26065893 DOI: 10.1038/ncomms8333] [Cited by in Crossref: 135] [Cited by in F6Publishing: 130] [Article Influence: 22.5] [Reference Citation Analysis]
87 Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy 2015;7:1187-99. [PMID: 26370838 DOI: 10.2217/imt.15.77] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 14.0] [Reference Citation Analysis]
88 Tai YT, Anderson KC. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. Expert Opin Biol Ther 2019;19:1143-56. [PMID: 31277554 DOI: 10.1080/14712598.2019.1641196] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 12.5] [Reference Citation Analysis]
89 Caers J, Garderet L, Kortüm KM, O'Dwyer ME, van de Donk NWCJ, Binder M, Dold SM, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, Dimopoulos MA, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner HW, Terpos E, Engelhardt M. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica 2018;103:1772-84. [PMID: 30171031 DOI: 10.3324/haematol.2018.189159] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 13.0] [Reference Citation Analysis]
90 Wang X, Walter M, Urak R, Weng L, Huynh C, Lim L, Wong CW, Chang WC, Thomas SH, Sanchez JF, Yang L, Brown CE, Pichiorri F, Htut M, Krishnan AY, Forman SJ. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Clin Cancer Res 2018;24:106-19. [PMID: 29061640 DOI: 10.1158/1078-0432.CCR-17-0344] [Cited by in Crossref: 64] [Cited by in F6Publishing: 45] [Article Influence: 16.0] [Reference Citation Analysis]
91 Liu D. Cancer biomarkers for targeted therapy. Biomark Res 2019;7:25. [PMID: 31807308 DOI: 10.1186/s40364-019-0178-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
92 Martínez-Cingolani C, Bories JC. Development of chimeric antigen receptors for multiple myeloma. Biochem Soc Trans 2016;44:397-405. [PMID: 27068946 DOI: 10.1042/BST20150280] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
93 Grywalska E, Sosnowska-Pasiarska B, Smok-Kalwat J, Pasiarski M, Niedźwiedzka-Rystwej P, Roliński J. Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy. Cells 2020;9:E983. [PMID: 32316105 DOI: 10.3390/cells9040983] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
94 Parrondo RD, Majeed U, Sher T. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis. Br J Haematol 2020;191:673-81. [PMID: 32298469 DOI: 10.1111/bjh.16697] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Maglione PJ, Ko HM, Tokuyama M, Gyimesi G, Soof C, Li M, Sanchez E, Chen H, Radigan L, Berenson J, Cunningham-Rundles C. Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies. J Allergy Clin Immunol Pract 2020;8:283-291.e1. [PMID: 31430592 DOI: 10.1016/j.jaip.2019.08.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
96 Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 2020;34:985-1005. [PMID: 32055000 DOI: 10.1038/s41375-020-0734-z] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 72.0] [Reference Citation Analysis]
97 Kampa M, Notas G, Stathopoulos EN, Tsapis A, Castanas E. The TNFSF Members APRIL and BAFF and Their Receptors TACI, BCMA, and BAFFR in Oncology, With a Special Focus in Breast Cancer. Front Oncol 2020;10:827. [PMID: 32612943 DOI: 10.3389/fonc.2020.00827] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
98 Miyazaki Y, Niino M, Takahashi E, Suzuki M, Mizuno M, Hisahara S, Fukazawa T, Amino I, Nakano F, Nakamura M, Akimoto S, Minami N, Fujiki N, Doi S, Shimohama S, Terayama Y, Kikuchi S. Fingolimod induces BAFF and expands circulating transitional B cells without activating memory B cells and plasma cells in multiple sclerosis. Clinical Immunology 2018;187:95-101. [DOI: 10.1016/j.clim.2017.10.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
99 Leblay N, Maity R, Hasan F, Neri P. Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities. Front Oncol 2020;10:636. [PMID: 32432039 DOI: 10.3389/fonc.2020.00636] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
100 George LL, Deshpande SR, Cortese MJ, Kendall EK, Chattaraj A, Shah Z, Zhao J, Anwer F. Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review. Clin Lymphoma Myeloma Leuk 2021:S2152-2650(21)00208-1. [PMID: 34253497 DOI: 10.1016/j.clml.2021.06.003] [Reference Citation Analysis]
101 Becnel MR, Lee HC. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma. Ther Adv Hematol 2020;11:2040620720979813. [PMID: 33403093 DOI: 10.1177/2040620720979813] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
102 Lin Q, Zhao J, Song Y, Liu D. Recent updates on CAR T clinical trials for multiple myeloma. Mol Cancer 2019;18:154. [PMID: 31684964 DOI: 10.1186/s12943-019-1092-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 21.5] [Reference Citation Analysis]
103 Egan PA, Elder PT, Deighan WI, O'Connor SJM, Alexander HD. Multiple myeloma with central nervous system relapse. Haematologica 2020;105:1780-90. [PMID: 32414852 DOI: 10.3324/haematol.2020.248518] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
104 Lee L, Bounds D, Paterson J, Herledan G, Sully K, Seestaller-wehr LM, Fieles WE, Tunstead J, Mccahon L, Germaschewski FM, Mayes PA, Craigen JL, Rodriguez-justo M, Yong KL. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br J Haematol 2016;174:911-22. [DOI: 10.1111/bjh.14145] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 13.4] [Reference Citation Analysis]
105 Tan CR, Shah UA. Targeting BCMA in Multiple Myeloma. Curr Hematol Malig Rep 2021;16:367-83. [PMID: 34432234 DOI: 10.1007/s11899-021-00639-z] [Reference Citation Analysis]
106 Pan J, Sun Y, Zhang N, Li J, Ta F, Wei W, Yu S, Ai L. Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance. Oncol Lett 2017;14:2657-62. [PMID: 28928810 DOI: 10.3892/ol.2017.6528] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
107 Borhis G, Trovato M, Chaoul N, Ibrahim HM, Richard Y. B-Cell-Activating Factor and the B-Cell Compartment in HIV/SIV Infection. Front Immunol 2017;8:1338. [PMID: 29163465 DOI: 10.3389/fimmu.2017.01338] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
108 Ma L, Liu X, Wang F, He X, Chen S, Li W. Different Donor Cell Culture Methods Can Influence the Developmental Ability of Cloned Sheep Embryos. PLoS One 2015;10:e0135344. [PMID: 26291536 DOI: 10.1371/journal.pone.0135344] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
109 Cho SF, Lin L, Xing L, Li Y, Yu T, Anderson KC, Tai YT. BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma. Cancers (Basel) 2020;12:E1473. [PMID: 32516895 DOI: 10.3390/cancers12061473] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 18.0] [Reference Citation Analysis]
110 Isola I, Moreno DF, Moga E, Mena MP, Tovar N, Rodríguez-Lobato LG, Oliver-Caldés A, Salgado MC, Brasó-Maristany F, Yagüe J, Cibeira MT, Prat A, Rosiñol L, Bladé J, Fernández de Larrea C. Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. Ann Hematol 2021. [PMID: 34463804 DOI: 10.1007/s00277-021-04653-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Gagelmann N, Ayuk F, Atanackovic D, Kröger N. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis. Eur J Haematol 2020;104:318-27. [PMID: 31883150 DOI: 10.1111/ejh.13380] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 15.0] [Reference Citation Analysis]
112 Hudecek M, Einsele H. Myeloma CARs are rolling into the clinical arena. Blood 2016;128:1667-8. [PMID: 27688779 DOI: 10.1182/blood-2016-08-729467] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
113 Atrash S, Ali SA, Usmani SZ. Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2021;21:21-34. [PMID: 33046423 DOI: 10.1016/j.clml.2020.08.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Kinneer K, Flynn M, Thomas SB, Meekin J, Varkey R, Xiao X, Zhong H, Breen S, Hynes PG, Fleming R, Bezabeh B, Chen C(, Wetzel L, Chen R, Dimasi N, Tai Y, Anderson KC, Herbst R, Howard PW, Hurt EM, Tice DA. Preclinical assessment of an antibody–PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells. Leukemia 2019;33:766-71. [DOI: 10.1038/s41375-018-0278-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 13.0] [Reference Citation Analysis]
115 Bal S, Giri S, Godby KN, Costa LJ. New regimens and directions in the management of newly diagnosed multiple myeloma. Am J Hematol 2021;96:367-78. [PMID: 33393136 DOI: 10.1002/ajh.26080] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Cho SF, Lin L, Xing L, Yu T, Wen K, Anderson KC, Tai YT. Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma. Antibodies (Basel) 2017;6:E18. [PMID: 31548533 DOI: 10.3390/antib6040018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
117 Fayon M, Martinez-Cingolani C, Abecassis A, Roders N, Nelson E, Choisy C, Talbot A, Bensussan A, Fermand JP, Arnulf B, Bories JC. Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma. Haematologica 2021;106:1193-7. [PMID: 32675220 DOI: 10.3324/haematol.2019.242453] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]